专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2017182350A1 SHELLAC MICROCAPSULE FORMULATIONS AND COMPOSITIONS 审中-公开
标题翻译： SHELLAC MICROCAPSULE制剂和组合物
公开(公告)号：WO2017182350A1
公开(公告)日：2017-10-26
申请号：PCT/EP2017/058741
申请日：2017-04-12
申请人： CONARIS RESEARCH INSTITUTE AG , CHRISTIAN-ALBRECHTS-UNIVERSITÄT ZU KIEL
发明人： WÄTZIG, Georg , SCHWARZ, Karin , KEPPLER, Julia , THEISMANN, Eva-Maria , KNIPP, Jörg , ELLRICHMANN, Mark , SCHREIBER, Stefan
IPC分类号： A61K9/14 , A61K9/16 , A61K9/28 , A61K9/48 , A61K9/50 , A61K31/19
摘要： The present invention relates to microcapsules comprising a core containing an active substance, which are characterised by a coating layer system comprising two layers of shellac and a pH-modulating substance provided between the two layers of shellac.
摘要翻译：本发明涉及包含含有活性物质的芯的微胶囊，其特征在于涂层系统包含两层虫胶和在两层虫胶之间提供的pH调节物质。 / p>

2. 发明申请

WO2017182347A1 SHELLAC MICROCAPSULE FORMULATIONS AND COMPOSITIONS FOR TOPICAL INTESTINAL DELIVERY OF VITAMIN B3 审中-公开
标题翻译：维生素B3局部肠道给药的壳聚糖微胶囊制剂和组合物
公开(公告)号：WO2017182347A1
公开(公告)日：2017-10-26
申请号：PCT/EP2017/058733
申请日：2017-04-12
申请人： CONARIS RESEARCH INSTITUTE AG , CHRISTIAN-ALBRECHTS-UNIVERSITÄT ZU KIEL
发明人： SCHWARZ, Karin , KEPPLER, Julia , THEISMANN, Eva-Maria , KNIPP, Jörg , FANGMANN, Daniela , LAUDES, Matthias , SCHREIBER, Stefan , WÄTZIG, Georg
IPC分类号： A61K9/14 , A61K9/16 , A61K9/28 , A61K9/48 , A61K9/50 , A61K31/19 , A61K31/455
摘要： The present invention relates to microcapsules comprising a core containing vitamin B3, which are characterised by a coating layer system comprising two layers of shellac and a pH-modulating substance provided between the two layers of shellac.
摘要翻译：本发明涉及包含含维生素B3的核心的微胶囊，其特征在于涂层系统包含两层虫胶和在两层虫胶之间提供的pH调节物质。 p>

3. 发明申请

WO2021250069A1 PHARMACEUTICAL COMPOUND FOR THE TREATMENT OF ATHEROSCLEROTIC CARDIOVASCULAR DISEASE 审中-公开
公开(公告)号：WO2021250069A1
公开(公告)日：2021-12-16
申请号：PCT/EP2021/065407
申请日：2021-06-09
申请人： CHRISTIAN-ALBRECHTS-UNIVERSITÄT ZU KIEL
发明人： SCHULTE, Dominik , WÄTZIG, Georg , LAUDES, Matthias , SCHREIBER, Stefan
IPC分类号： C07K14/705 , A61P3/06 , A61P9/12 , A61P9/00 , C07K14/70503 , C07K2319/00 , C07K2319/30
摘要： The invention provides a polypeptide dimer comprising two gp130-Fc fusion peptides for use in the treatment of ASCVD in human patients, preferably of high-risk ASCVD in human patients, more preferably of very-high-risk ASCVD in human patients.

4. 发明申请

WO2022112489A1 NICOTINAMIDE, NICOTINAMIDE PRECURSORS AND NICOTINAMIDE METABOLITES AND COMPOSITIONS THEREOF FOR REDUCING THE TIME TO RESOLUTION OF SYMPTOMS IN PATIENTS WITH COVID-19 AND OTHER VIRAL INFECTIONS 审中-公开
公开(公告)号：WO2022112489A1
公开(公告)日：2022-06-02
申请号：PCT/EP2021/083138
申请日：2021-11-26
申请人： CONARIS RESEARCH INSTITUTE AG
发明人： WÄTZIG, Georg , SCHREIBER, Stefan
IPC分类号： A61K31/455 , A61K31/198 , A61K31/405 , A61K31/706 , A61K31/7084 , A61P31/12 , A61P31/14 , A61P31/16 , A61P31/18 , A61P31/20
摘要： The present invention relates to nicotinamide (niacinamide) or suitable precursors or metabolites thereof and compositions thereof for use for reducing the time to resolution of one or more symptoms in patients with COVID-19 or in patients with other viral infections.

5. 发明申请

WO2015086843A2 A PHARMACEUTICAL COMPOSITION CONTAINING NICOTINIC ACID AND/OR NICOTINAMIDE FOR BENEFICIALLY INFLUENCING BLOOD LIPID LEVELS BY MODIFYING THE INTESTINAL MICROBIOTA 审中-公开
标题翻译：含有烟碱酸和/或烟酰胺的药物组合物通过改变肠道微生物来有益地影响血脂水平
公开(公告)号：WO2015086843A2
公开(公告)日：2015-06-18
申请号：PCT/EP2014/077646
申请日：2014-12-12
申请人： CONARIS RESEARCH INSTITUTE AG
发明人： WÄTZIG, Georg , SEEGERT, Dirk
CPC分类号： A61K31/455 , A61K9/0031 , A61K9/0053 , A61K9/4891 , A61K9/5026 , A61K9/5047 , A61K9/5073 , A61K45/06
摘要： The present invention relates to a new pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or related compounds for beneficially influencing the intestinal microbiota and blood lipid levels. In certain embodiments, the pharmaceutical composition is partially or entirely released into the lower small intestine and/or large intestine.
摘要翻译：本发明涉及含有烟酸和/或烟酰胺和/或用于有益地影响肠微生物群和血脂水平的相关化合物的新型药物组合物。在某些实施方案中，药物组合物被部分或全部释放到下部小肠和/或大肠中。

6. 发明申请

WO2006021453A2 OPTIMIZED NUCLEOTIDE SEQUENCES ENCODING SGP 130 审中-公开
标题翻译：编码SGP的优化的核苷酸序列130
公开(公告)号：WO2006021453A2
公开(公告)日：2006-03-02
申请号：PCT/EP2005/009247
申请日：2005-08-26
申请人： CONARIS RESEARCH INSTITUTE AG , SEEGERT, Dirk , WÄTZIG, Georg , RAHAUS, Nikolaus , DAECKE, Jessica , ROSE-JOHN, Stefan
发明人： SEEGERT, Dirk , WÄTZIG, Georg , RAHAUS, Nikolaus , DAECKE, Jessica , ROSE-JOHN, Stefan
IPC分类号： C07K14/715 , C12N15/113 , C12N15/67
CPC分类号： C07K14/7155 , C12N15/1138
摘要： Described are codon optimized sgpl30 encoding nucleic acid molecules as well as a method for the highly efficient recombinant production of sgpl30 in mammalian cells or bacteria using a nucleic acid molecule of the invention.
摘要翻译：描述了密码子优化的sgp130编码核酸分子以及使用本发明的核酸分子在哺乳动物细胞或细菌中高效重组生产sgp130的方法。

7. 发明申请

WO2015124637A1 METHODS AND COMPOSITIONS FOR INTESTINAL MICROENVIRONMENT TRANSFER 审中-公开
标题翻译：用于内源微环境转移的方法和组合物
公开(公告)号：WO2015124637A1
公开(公告)日：2015-08-27
申请号：PCT/EP2015/053433
申请日：2015-02-18
申请人： CONARIS RESEARCH INSTITUTE AG
发明人： WÄTZIG, Georg , SEEGERT, Dirk
IPC分类号： A61K35/24 , A61P1/00
CPC分类号： A61K35/24 , Y02A50/475
摘要： The present invention relates to novel methods and compositions for positively influencing or normalising the human intestinal microbiota. The invented technique is termed intestinal microenvironment transfer (IMEnT) and comprises the preparation of a mixture of metabolites, nutrients and mediators produced by both the intestinal microbiota and the body cells of a healthy animal, especiallymammal, andparticularlypig or human, donor and transfer of this mixture (the IMEnT preparation)to a recipient of the same or another species suffering from intestinal dysbiosis in order to revitalise and/or normalise the recipient's endogenous microbiota. In particular, the present invention relates to pharmaceutical compositions and formulations as well as dietary supplements for specific and/or selective delivery of the IMEnT preparations into the small intestine and/or the large intestine.
摘要翻译：本发明涉及用于阳性影响或归一化人肠道微生物群的新方法和组合物。本发明的技术被称为肠微环境转移（IMEnT），并且包括制备由健康动物，特别是马氏，特别是人，供体和转移的健康动物的肠微生物群和体细胞产生的代谢物，营养物和介质的混合物混合物（IMEnT制剂）给患有肠道生态系统的相同或另一种物种的接受者，以便振兴和/或使接受者的内源性微生物群体正常化。特别地，本发明涉及用于将IMEnT制剂特异性和/或选择性递送到小肠和/或大肠中的药物组合物和制剂以及膳食补充剂。

8. 发明申请

WO2015086838A2 A PHARMACEUTICAL COMPOSITION CONTAINING COMBINATIONS OF NICOTINAMIDE AND 5-AMINOSALICYLIC ACID FOR BENEFICIALLY INFLUENCING THE INTESTINAL MICROBIOTA AND/OR TREATING GASTROINTESTINAL INFLAMMATION 审中-公开
标题翻译：含有NICOTINAMIDE和5-氨基乙酸的组合的药物组合物，用于有益于影响细胞内微生物和/或治疗胃肠道炎症
公开(公告)号：WO2015086838A2
公开(公告)日：2015-06-18
申请号：PCT/EP2014/077637
申请日：2014-12-12
申请人： CONARIS RESEARCH INSTITUTE AG
发明人： WÄTZIG, Georg , SEEGERT, Dirk
CPC分类号： A61K31/606 , A61K9/0031 , A61K9/0053 , A61K9/5047 , A61K31/455 , A61K45/06 , A61K2300/00
摘要： The present invention relates to a new pharmaceutical composition containing a combination of 5-aminosalicylic acid and nicotinamide or related compounds. The combination is believed to beneficially influence the intestinal microbiota and/or reduce gastrointestinal inflammation. In certain embodiments, the pharmaceutical composition is partially or entirely released into the small intestine or large intestine.
摘要翻译：本发明涉及含有5-氨基水杨酸和烟酰胺或相关化合物的组合的新药物组合物。该组合被认为有益地影响肠道微生物群和/或减少胃肠道炎症。在某些实施方案中，药物组合物部分或完全释放到小肠或大肠中。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式